stockrow
Monday 9 November 2026
Export DHAI’s income statement to Excel — free account
DIH Holding US, Inc.
DHAIDIH Holding US, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $62.9 million, down 2.50% from fiscal 2024.
- Revenue
- −30.7%
- EPS
- +43.1%
- Free cash flow
- −167.9%
Quarter to March 2025, against a year earlier
0.00
0.00
NaN
Follow DHAI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 54 | 64 | 63 | +7.8% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 56.58 | 46.18 | 51.24 | (5.3) pt | ||||||
| EBT | — | — | — | — | — | 0 | 7 | 1 | (7) | (8) | +436.2% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (11.16) | (13.15) | (13.1) pt | ||||||
| Net income | — | 0 | — | — | — | 0 | 7 | 1 | (8) | (9) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 61.10 | 43.95 | n/m | |||||
| Earnings | — | — | — | — | — | (0.05) | 31.06 | 2.99 | (8.00) | (6.07) | +232.3% | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (5.16) | (3.24) | 4.92 | (2.90) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.19) | (0.37) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (5.16) | (3.24) | 4.73 | (3.27) | n/m | ||||||
| Book value | — | — | — | — | — | 0.08 | (35.85) | (55.79) | (30.84) | (25.96) | n/m | ||||||
| Shares, m | — | — | — | — | — | 0 | 0 | 0 | 1 | 1 | +63.5% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 23.53 | 0.00 | 0.00 | 7.8 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.14 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.29 | 0.1 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (3,643.81) | 6.96 | (3.89) | (1,213.6) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (1) | 5 | (4) | n/m | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | (1) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (1) | 5 | (5) | n/m | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 0 | (5) | (18) | (22) | +193.5% | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 2 | 8 | 9 | +167.7% | ||||||
| Shareholders’ equity | — | — | — | — | — | 0 | (8) | (12) | (33) | (37) | n/m | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (5.36) | 6.36 | 1.42 | (17.89) | (27.77) | (22.4) pt | |||||
| ROIC | — | — | — | — | — | (3.25) | 0.00 | 0.00 | 0.00 | 0.00 | +3.3 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | (173.87) | (3.13) | 37.95 | 24.90 | +24.9 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | 3 | 242 | 192 | 178 | +290.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.34 | 0.35 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2025 · latest quarter Mar 2025 · fundamentals updated 26 Oct 2026
DIH Holding US, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BJDX Bluejay Diagnostics, Inc. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.6M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.3M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| NUVOQ Holdco Nuvo Group D.G Ltd. | $2.1M | — (loss-making) | — | — | n/m | −1.05% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADGM Adagio Medical Holdings, Inc. | $1.8M | — (loss-making) | — | −33.50% (below 0%: shrinking) | n/m | −12.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NXL Nexalin Technology, Inc. | $1.7M | — (loss-making) | — (loss-making) | −82.72% (below 0%: shrinking) | n/m | −97.23% (below 0%: shrinking) | 72.95% | (18,420.49%) | Compare |
| GCTK GlucoTrack, Inc. | $1.7M | — (loss-making) | — (loss-making) | +342.48% (above 0%: growing) | n/m | +3.42% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DHAI DIH Holding US, Inc. | $1.6M | — (loss-making) | — | −30.67% (below 0%: shrinking) | n/m | −167.90% (below 0%: shrinking) | 50.33% | (33.62%) | |
| Median of peers | $2.2M | — | — | +0.64% | — | +3.65% | 16.19% | (29.64%) |